ArticleJAMA network open2024
Survival in Patients With De Novo Metastatic Prostate Cancer.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.Future oncology (London, England) · 2025Trial
- Clinical significance of circulating macrophage markers across different stages of prostate cancer: highlighting soluble CD163.British journal of cancer · 2026Article
- Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.Future oncology (London, England) · 2026Article
- Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.JCO precision oncology · 2026Article
- Treatment and progression of patients in Sweden with metastatic castration-sensitive prostate cancer.Acta oncologica (Stockholm, Sweden) · 2026Article
- Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer.The oncologist · 2026Article
- Integration of Darolutamide in the Treatment Landscape for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis of Efficacy and Safety.European urology open science · 2026Article
- Latent profile analysis of fear of cancer recurrence in patients with prostate cancer: Insights into risk factors and psychological interventions.Asia-Pacific journal of oncology nursing · 2025Article
- Abiraterone vs Enzalutamide Among US Veterans With Metastatic Hormone-Sensitive Prostate Cancer.JAMA network open · 2025Article
- Article
- The natural history of prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Review
- Treatment Patterns and Survival Among Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer.JAMA network open · 2025Article
- Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.International journal of clinical oncology · 2025Article
- Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.European urology open science · 2025Article
- Cardiovascular Risk in Prostate Cancer:JACC. CardioOncology · 2024Review
- The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer.Urology practice · 2024Article
- The Circulating miR-107 as a Potential Biomarker Up-Regulated in Castration-Resistant Prostate Cancer.Non-coding RNA · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.